Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Voyager Therapeutics (VYGR) EPS (Basic): 2015-2025

Historic EPS (Basic) for Voyager Therapeutics (VYGR) over the last 11 years, with Sep 2025 value amounting to -$0.47.

  • Voyager Therapeutics' EPS (Basic) fell 193.75% to -$0.47 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.17, marking a year-over-year decrease of 414.49%. This contributed to the annual value of -$1.13 for FY2024, which is 136.69% down from last year.
  • According to the latest figures from Q3 2025, Voyager Therapeutics' EPS (Basic) is -$0.47, which was up 17.54% from -$0.57 recorded in Q2 2025.
  • Over the past 5 years, Voyager Therapeutics' EPS (Basic) peaked at $3.05 during Q1 2023, and registered a low of -$0.80 during Q2 2021.
  • Moreover, its 3-year median value for EPS (Basic) was -$0.47 (2025), whereas its average is $0.04.
  • As far as peak fluctuations go, Voyager Therapeutics' EPS (Basic) crashed by 513.33% in 2022, and later soared by 644.64% in 2023.
  • Quarterly analysis of 5 years shows Voyager Therapeutics' EPS (Basic) stood at $0.15 in 2021, then plummeted by 513.33% to -$0.62 in 2022, then soared by 298.39% to $1.23 in 2023, then tumbled by 148.78% to -$0.60 in 2024, then plummeted by 193.75% to -$0.47 in 2025.
  • Its last three reported values are -$0.47 in Q3 2025, -$0.57 for Q2 2025, and -$0.53 during Q1 2025.